All the Active Ingredient Drugs
Immunoglobulins. Human Normal Immunoglobulin 160 mg/ml. PFS: 1 x 2 cc, 5 cc. See lit.
Defic. defect. antibody synth., protracted
transitory hypogammaglobulem.,
proph. hepatit. A, measles or attenuat.
measles.
C/I: Severe thrombocytopen., other
coag. disords., isolated immunoglobulin
A (IgA) defic.
Human Normal Immunoglobulin 0.5 g / 10 ml. VIALS: 1 x 0.5 g, 2.5 g, 5 g, 10 g. See lit.
Replacement ther. in: Prim. immunodefic.
synds. such as: congen.
agammaglobulinem./
hypogammaglobulinem; common
variable immunodefic.; severe combined
immunodefic.; Wiscott Aldrich syndr.
Myeloma/chron. lympocyt. leukem. with
severe second. hypogammaglobuline.
and recurr. infects. Child with congenital
AIDS and recurr. infects.
Immunomodulat: ITP in child or adults at
high risk of bleed./prior to surgery to
correct the platelet count. Guillain Barre
syndr., Kawasaki dis., allogeneic bone
marrow transplant.
C/I: History anaphylact. or severe
system. response to I.M./I.V.
immunoglob. preps.
Human Normal Immunoglobulin 0.1 gr/ml. VIAL: 1 x 10 ml, 25 ml, 50 ml, 100 ml.
See lit.
Prim. immunodefic. (PI), idiopath.
thrombocytopen. purpura (ITP). Chron.
inflamm. demyelinat. polyneuropath.
(CIDP).
C/I: Known anaphylact./severe system.
response to human immunoglob.,
severe select. IgA defic. See lit.
Immunoglobulins. Human Normal Immunoglobulin 100 g/l. VIAL (sol.for infus.): 10, 25, 50, 100, 200 ml.
Replacem. ther. in primary immunodefic., init. dose: 0.4-0.8 g/kg, thereafter 0.2-0.8 g/kg every 3-4 wks. to obtain IgG trough level of IgG of at least 6 g/l. Replacem. ther. in second. immunodefic.: 0.2-0.4 g/kg, every 3-4 wks. Prim. immune thrombocytop.: 0.8-1 g/kg on day 1, possibly rpt once within 3 days, or 0.4 g/kg/d for 2-5 d. Guillain Barré syndr.: 0.4 g/kg/d for 5 d (possible rpt of dosing in case of relapse). Kawasaki dis.: 2 g/kg should be admin. as a sgle. dose. Pts should receive concom. tmt with acetylsalicylic acid. CIDP Starting dose: 2 g/kg div. over 2 -5 consecutive d. Mainten. doses: 1 g/kg over 1-2 consecutive d every 3 wks. MMN starting dose: 2 g/kg given over 2-5 consecut. days. Mainten. dose: 1 g/kg every 2 to 4 wks or 2 g/kg every 4 to 8 wks. Replacem. ther. in adults, child. and adolesc. (0-18 years) in: Primary immunodefic. syndr. (PID) with impair. antibod. prod. Second. Immunodefic. (SID) in pts with sev. or recur. infect., ineffective antimicrob. tmt and either PSAF or serum IgG level of <4 g/l. Immunomodul. in adults, child. and adolesc. (0-18 years) in:Primary ITP, in pts at high risk of bleed. or prior to surg. to correct platelet count. Guillain Barré syndr. Kawasaki dis. (in conjunct. w/acetylsalicylic acid). Chronic inflamm. demyelin. polyradiculoneuropathy (CIDP). Multifocal motor neuropathy (MMN).
C/I: Hypersens. to the active subst. or to any of the excip. Pts. with selective IgA defic. who develop antibod. to IgA, as admin. of IgA-contain. product can result in anaphylax.
Immunoglobulins. Human Normal Immunoglobulin 50 mg/ml. VIAL (sol.for infus.): 20, 50, 100, 200 ml.
Replacem. ther. in primary immunodefic., init. dose: 0.4-0.8 g/kg, thereafter 0.2-0.8 g/kg every 3-4 wks. to obtain IgG trough level of IgG of at least 6 g/l. Replacem. ther. in second. immunodefic.: 0.2-0.4 g/kg, every 3-4 wks. Prim. immune thrombocytop.: 0.8-1 g/kg on day 1, possibly rpt once within 3 days, or 0.4 g/kg/d for 2-5 d. Guillain Barré syndr.: 0.4 g/kg/d for 5 d (possible rpt of dosing in case of relapse). Kawasaki dis.: 2 g/kg should be admin. as a sgle. dose. Pts should receive concom. tmt with acetylsalicylic acid. CIDP Starting dose: 2 g/kg div. over 2 -5 consecutive d. Mainten. doses: 1 g/kg over 1-2 consecutive d every 3 wks. MMN starting dose: 2 g/kg given over 2-5 consecut. days. Mainten. dose: 1 g/kg every 2 to 4 wks or 2 g/kg every 4 to 8 wks. Replacem. ther. in adults, child. and adolesc. (0-18 years) in: Primary immunodefic. syndr. (PID) with impair. antibod. prod. Second. Immunodefic. (SID) in pts with sev. or recur. infect., ineffective antimicrob. tmt and either PSAF or serum IgG level of <4 g/l. Immunomodul. in adults, child. and adolesc. (0-18 years) in:Primary ITP, in pts at high risk of bleed. or prior to surg. to correct platelet count. Guillain Barré syndr. Kawasaki dis. (in conjunct. w/acetylsalicylic acid). Chronic inflamm. demyelin. polyradiculoneuropathy (CIDP). Multifocal motor neuropathy (MMN).
C/I: Hypersens. to the active subst. or to any of the excip. Pts. with selective IgA defic. who develop antibod. to IgA, as admin. of IgA-contain. product can result in anaphylax.
Human Normal Immunoglobulin 100 mg/ml. VIAL (sol. for infus.): 1 x 10, 25, 50, 100,
200, 300 ml. See lit.
Replace. ther. in : Prim. immunodefic
syndrs. with impaired antibody product.,
hypogammaglobulinem., recurr. bact.
infects. with chron. lymphoc. leukem. in
whom prophylact. antibiotics failed,
hypogammaglobulinem. and recurr.
bact. infects in plateau phase multiple
myeloma with failed response to
pneumococc. imunizat., child and
adolesc. (0-18 yrs) with congen. AIDS and
recurr. bact. infects.,
hypogammaglobulinem. aft. allogen.
hematopoiet. stem cell transplant.
(HSCT). Immunomodulat: Primary
immune thrombocytopenia (ITP), in high
risk of bleed/prior to surg. to correct
platelet count. Guillain Barre syndr.,
Kawasaki dis.
C/I: Hypersens. to product., to human
immunoglobulins. See lit.